FectoVIR®-LV transfection reagents

Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases.FectoVIR^®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR^®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs.

Key benefits

• Productivity - reach the highest Lentiviral vectors titers in suspension systems
• Cost-Effectiveness - reduce your cost per batch with high titers and low DNA consumption
• Scalability - produce at large scale with low complexation volume and long complex stability
• Time-Saving - use DOE service to help you optimizing your process in a record time

Specifications:

Source: www.sartorius.com